Spectrum Pharmaceuticals Buys Remaining Rights To Compound

Irvine-based Spectrum Pharmaceuticals has acquired the remaining rights to RenaZorb, the firm's nanotechnology compound being used for treating hyperphosphatemia in patients with chronic kidney disease. The firm said it is paying $750,000 in restricted common stock for the rights to owner Altair Nanotechnologies. Spectrum had acquired a worldwide license to the compound in 2005.